How inflammation affects RUNX1-related familial platelet disorder and leukemia risk
Contribution of Inflammation to the Pathogenesis of RUNX1-FPDMM
['FUNDING_OTHER'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-11284303
Researchers are looking at how inflammation changes blood and bone marrow cells in people with RUNX1-FPDMM, a genetic condition that raises the chance of developing acute myeloid leukemia.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-11284303 on ClinicalTrials.gov |
What this research studies
From a patient perspective, the team will analyze blood and bone marrow samples from people with RUNX1-FPDMM and related AML to see how inflammatory signals alter cell behavior. They will use genomic approaches, including large-scale CRISPR screens and analysis of patient-derived datasets, to map pathways that let cancer cells survive treatment. Lab models and multi-institution collaborations will be used to test combinations of drugs that might block those resistance mechanisms. The work builds on extensive existing datasets and aims to move promising findings toward clinical trials.
Who could benefit from this research
Good fit: People diagnosed with RUNX1-FPDMM or acute myeloid leukemia, especially those able to give blood or bone marrow samples or join related clinical efforts, would be the most relevant candidates.
Not a fit: Patients who do not have RUNX1 mutations or who have unrelated non-blood conditions are unlikely to see direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could point to new drug combinations or targets that reduce relapse and improve long-term outcomes for people with RUNX1-FPDMM or AML.
How similar studies have performed: The investigators have previously generated large genomic datasets and helped translate findings into clinical trials, though the specific focus on inflammation in RUNX1-FPDMM is relatively new.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AGARWAL, ANUPRIYA — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: AGARWAL, ANUPRIYA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.